Cargando…
Evaluation in alcohol use disorders – insights from the nalmefene experience
Nalmefene was the first treatment approved by the European Medicines Agency for reducing alcohol consumption in adult patients with alcohol dependence. It is often presented as a paradigm shift in therapeutics, but major issues limit the interpretation of the evidence supporting its use. The randomi...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989362/ https://www.ncbi.nlm.nih.gov/pubmed/27534932 http://dx.doi.org/10.1186/s12916-016-0664-9 |